Administration – Defibrotide is administered 6.25 mg/kg every 6 hours intravenously for ≥21 days, until SOS resolution or hospital discharge, up to a maximum of 60 days [85]. Defibrotide should be discontinued ≥2 hours prior to invasive procedures and can be resumed once any procedure-related risk of bleeding is resolved. There is no known reversal agent, but the half-life of elimination is